Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 1, 2005, Pages 164-169

  Tarao, Kazuo ^a   Fujiyama, Shigetoshi ^c   Ohkawa, Shinichi ^a   Miyakawa, Kaoru ^a   Tamai, Setsuo ^a   Hirokawa, Satora ^a   Masaki, Takahiro ^a   Tanaka, Katsuaki ^b  

^a KANAGAWA CANCER CENTER   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; NEOMINOPHAGEN C; URSODEOXYCHOLIC ACID; XIAO CHAI HU TANG;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CANCER RISK; CHEMOPROPHYLAXIS; DISEASE ASSOCIATION; DRUG DOSE REGIMEN; DRUG EFFICACY; FOLLOW UP; HEPATITIS; HEPATITIS C VIRUS; HUMAN; INCIDENCE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK FACTOR;

ALANINE TRANSAMINASE; ANALYSIS OF VARIANCE; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, NEOPLASTIC; CHOLAGOGUES AND CHOLERETICS; DRUG THERAPY, COMBINATION; DRUGS, CHINESE HERBAL; FEMALE; GLYCYRRHIZIC ACID; HEPACIVIRUS; HEPATITIS C; HUMANS; INCIDENCE; INFLAMMATION; LIVER CIRRHOSIS; LIVER NEOPLASMS; LOGISTIC MODELS; MALE; MIDDLE AGED; RISK FACTORS; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 12844288888     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Tarao K, Rino Y, Ohkawa S, et al. Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus-associated cirrhosis. Cancer 1999;86:589-95.
2. Tarao K, Rino Y, Takemiya S, et al. Close association between high serum ALT and more rapid recurrence of hepatocellular carcinoma in hepatectomized patients with HCV-associated liver cirrhosis and hepatocellular carcinoma. Intervirology 2000;43:20-6.
3. Suzuki H, Ohta Y, Takino T, Fujisawa K, Hirayama C. Effects of glycyrrhizin on biochemical tests in patients with chronic hepatitis-double blind trial. Asian Med J 1983;26:423-8.
4. Hirayama C, Okumura M, Tanikawa K, Yano M, Mizuta M, Ogawa N. A multicenter randomized control clinical trial of Sho-saiko-to in chronic active hepatitis. Gastroenterol Jpn 1989;24:715-9.
5. Arase Y, Ikeda K, Murashima N, et al. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997;79:1494-500.
6. Oka H, Yamamoto S, Kuroki T, et al. Prospective study of chemoprevention of hepatocellular carcinoma with Sho-saiko-to (TJ-9). Cancer 1995;76:743-9.
7. Lindor KD, Dickson ER, Baldus WP, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994;106:1284-90.
8. O'Brien CB, Senior JR, Arora-Mirchandi R, et al. Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30 months pilot study. Hepatology 1991;14:838-47.
9. Beuers U, Spengler U, Kruis W, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo controlled trial. Hepatology 1992;16:707-14.
10. Bellentani S, Podda M, Tiribelli C, et al. Ursodiol in the long-term treatment of chronic hepatitis: a double-blind multicenter clinical trial. J Hepatol 1993;19:459-64.
11. Tung BY, Emond MJ, Haggitt RC, et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001;134:89-95.
12. Pardi DS, Loftus Jr EV, Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003;124:889-93.
13. 1 phase. Cancer Res 1994;54:448-54.
14. Sakaida I, Matsumura Y, Akiyama S, Hayashi K, Ishige A, Okita K. Herbal medicine Sho-saiko-to (TJ-9) prevents liver fibrosis and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. J Hepatol 1998;28:298-306.
15. Child CG III, Turcotte JG. Surgery and portal hypertension. In: Dunphy JE, editor. The liver and portal hypertension. Philadelphia: W.B. Saunders; 1964.
16. Yumoto Y, Jinno K, Tokuyama K, et al. Hepatocellular carcinoma detected by iodized oil. Radiology 1985;154:19-24.
17. Hino K, Miyakawa H, Takahashi J, et al. Histological improvement in inflammation in chronic hepatitis by administration of Stronger-Neo-Minophagen C (SNMC) [in Japanese]. Kan-Tan-Sui 1986;13:797-807.
18. Hirayama C, Shimada N, Tsuji T, et al. Clinical effect of Sho-saiko-to (TJ-9) in post-transfusion chronic hepatitis in Japan [in Japanese]. Shokakika 1991;15:50-6.
19. Tarao K, Tamai S, Ohkawa S, et al. The effects of combined drug therapy on the serum alanine aminotransferase levels in HCV-associated liver cirrhosis [in Japanese]. Rinsho-to Kenkyu 1998;75:1858-67.
20. Hosmer DW, Lemeshow S. Applied logistic regression. New York: John Wiley & Sons;1989.
21. Shetty K, Rybicki L, Brzezinski A, Carey WD, Lashner BA. The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 1999;94:1643-9.
22. Broome U, Lofberg R, Veress B, Eriksson LS. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 1995;22:1404-8.
23. Kornfeld D, Ekbom A, Ihre T. Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. Gut 1997;41:522-5.
24. Marchesa P, Lashner BA, Lavery IC, et al. The risk of cancer and dysplasia among ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 1997;92:1285-8.
25. Leidenius MH, Farkkila MA, Karkkainen P, Taskinen EI. Colorectal dysplasia and carcinoma in patients with ulcerative colitis and primary sclerosing cholangitis. Scand J Gastroenterol 1997;32:706-11.
26. Brentnall TA, Haggitt RC, Rabinovitch PS, et al. Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1996;110:331-8.
27. Broome U, Lindberg G, Lofberg R. Primary sclerosing cholangitis in ulcerative colitis - a risk factor for the development of dysplasia and DNA aneuploidy? Gastroenterology 1992;102:1877-80.
28. D'Haens GR, Lashner BA, Hanauer SB. Pericholangitis and sclerosing cholangitis are risk factors for dysplasia and cancer in ulcerative colitis. Am J Gastroenterol 1993;88:1174-8.
29. Bansal P, Sonnenberg A. Risk factors of colorectal cancer in inflammatory bowel disease. Am J Gastroenterol 1996;91:44-8.
30. Larson MV, McLeod RS, Beighley CM, Zinsmeister AR, Carlson HC, Colin P. Ursodeoxycholic acid for the prevention of metachronous adenomatous colorectal polyps: the results of a randomized controlled trial [abstract]. Am J Gastroenterol 2002;97:S118.
31. Serfaty L, De Leusse A, Rosmorduc O, et al. Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study. Hepatology 2003;38:203-9.
32. Earnest DL, Holubec H, Wali RK, et al. Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodexycholic acid. Cancer Res 1994;54:5071-4.
33. Oyama K, Shiota G, Ito H, Murawaki Y, Kawasaki H. Reduction of hepatocarcinogenesis by ursodeoxycholic acid in rats. Carcinogenesis 2002;23:885-92.
34. Tarao K, Rino Y, Ohkawa S, Tamai S, Miyakawa K, Takakura H, et al. Close association between high serum alanine aminotransferase levels and multicentric hepatocarcinogenesis in patients with hepatitis C virus-associated cirrhosis. Cancer 2002;94:1787-95.
35. Oka H, Kurioka N, Kim K, et al. Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology 1990;12:680-7.
36. Kaneko S, Unoura M, Takeuchi M, et al. The role of hepatitis C virus in hepatocellular carcinoma in Japan. Intervirology 1994;37:108-13.
37. Wali RK, Stoiber D, Nguyen L, et al. Ursodeoxycholic acid inhibits the initiation and postinitiation phases of azoxymethane-induced colonic tumor development. Cancer Epidemiol Biomarkers Prev 2002;11:1316-21.
38. Rodrigues CMP, Kren BT, Steer CJ, Setchell DR. The site-specific delivery of ursodeoxycholic acid to the rat colon by sulfate conjugation. Gastroenterology 1995;109:1835-44.
39. Ochsenkuhn T, Bayerdorffer E, Meining A, et al. Colonic mucosal proliferation is related to serum deoxycholic acid levels. Cancer 1999;85:1664-9.
40. Wilpart M, Mainguet P, Maskens A, Roberfroid M. Mutagenicity of 1,2-dimethylhydrazine towards Salmonella typhimurium, co-mutagenic effect of secondary biliary acids. Carcinogenesis 1983;4:45-8.
41. Martinez JD, Stratagoules ED, LaRue JM, et al. Different bile acids exhibit distinct biological effects: the tumor promoter deoxycholic acid induces apoptosis and the chemopreventive agent ursodeoxycholic acid inhibits cell proliferation. Nutr Cancer 1998;31:111-8.
42. Tarao K, Ohkawa S, Shimizu A, et al. Significance of hepatocellular proliferation in the development of hepatocellular carcinoma from anti-hepatitis C virus-positive cirrhotic patients. Cancer 1994;73:1149-54.
43. Khare S, Wali RK, Cerda SR, et al. Ursodeoxycholic acid and an analogue of vitamin D inhibit COX-2 expression in AOM-induced colonic tumors and in HCA-7 cells: roles of C/EBPβ and VEGF [abstract]. Gastroenterology 2001; 120:A170.
44. Khare S, Cerda S, Wali RK, et al. Ursodeoxycholic acid inhibits ras mutations, wild-type ras activation and cyclooxygenase-2 expression in colon cancer. Cancer Res 2003;63:3517-23.
45. Sheu JC, Sung JL, Chen DS, et al. Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology 1985;89:259-66.